Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies

Primary liver cancer, or hepatocellular carcinoma (HCC), is a major worldwide cause of death from carcinoma. Most patients are not candidates for surgery and medical therapies, including new immunotherapies, have not shown major improvements since the modest benefit seen with the introduction of sor...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 12; no. 12; p. 1243
Main Authors Stolley, Danielle L, Crouch, Anna Colleen, Özkan, Aliçan, Seeley, Erin H, Whitley, Elizabeth M, Rylander, Marissa Nichole, Cressman, Erik N K
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 20.12.2020
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Primary liver cancer, or hepatocellular carcinoma (HCC), is a major worldwide cause of death from carcinoma. Most patients are not candidates for surgery and medical therapies, including new immunotherapies, have not shown major improvements since the modest benefit seen with the introduction of sorafenib over a decade ago. Locoregional therapies for intermediate stage disease are not curative but provide some benefit. However, upon close scrutiny, there is still residual disease in most cases. We review the current status for treatment of intermediate stage disease, summarize the literature on correlative histopathology, and discuss emerging methods at micro-, nano-, and pico-scales to improve therapy. These include transarterial hyperthermia methods and thermoembolization, along with microfluidics model systems and new applications of mass spectrometry imaging for label-free analysis of pharmacokinetics and pharmacodynamics.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics12121243